Original article

Bacterial pulmonary superinfections are associated with unfavourable outcomes in critically ill COVID-19 patients

Philipp K. Buehler^{1*}, Annelies S. Zinkernagel^{2*}, Daniel A. Hofmaenner^{1*}, Pedro David Wendel García¹, Claudio T. Acevedo², Alejandro Gómez-Mejía², Srikanth Mairpady Shambat², Federica Andreoni², Martina A. Maibach¹, Jan Bartussek^{1,4}, Matthias P. Hilty¹, Pascal M. Frey³, Reto A. Schuepbach^{1**}, Silvio D. Brugger^{2**}

¹ Institute for Intensive Care Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland

² Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

³ Department of General Internal Medicine, Bern University Hospital, University of Bern, Bern, Switzerland

⁴ Department of Quantitative Biomedicine, University Hospital Zurich, and University of Zurich, Zurich, Switzerland

* These authors contributed equally to the work

** These authors contributed equally to the work

Running title: Superinfection in COVID-19 patients

Correspondence to:

Silvio D. Brugger, M.D., Ph.D.

Division of Infectious Diseases and Hospital Epidemiology

University Hospital Zurich

Raemistrasse 100

CH-8091 Zurich

Switzerland

Phone +41 44 255 25 41 E-Mail: silvio.brugger@usz.ch

35 **Keywords:** severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus
36 disease 19 (COVID-19), acute respiratory distress syndrome (ARDS), superinfection, coinfection
37

38 Abstract

39

40 Objectives

41 While superinfections are associated with unfavourable disease course, their impact on clinical
42 outcomes in critically ill COVID-19 patients remains largely unknown. We aimed to investigate
43 the burden of superinfections in COVID-19 patients.

44

45 Methods

46 In this prospective single centre cohort study in an intensive care setting patients aged ≥ 18 years
47 with COVID-19 acute respiratory distress syndrome were assessed for concomitant microbial
48 infections by longitudinal analysis of tracheobronchial secretions, bronchoalveolar lavages and
49 blood. Our primary outcome was ventilator-free survival on day 28 in patients with and without
50 clinically relevant superinfection. Further outcomes included the association of superinfection
51 with ICU length of stay, incidence of bacteremia, viral reactivations, and fungal colonization.

52

53 Results

54 In 45 critically ill COVID-19 patients, we identified 19 patients with superinfections (42.2%) by
55 longitudinal analysis of 433 TBS, 35 BAL and 455 blood samples, respectively. On average,
56 superinfections were detected on day 10 after ICU admission. The most frequently isolated
57 clinically relevant bacteria were Enterobacteriaceae, *Streptococcus pneumoniae*, and
58 *Pseudomonas aeruginosa*.

59 Ventilator-free survival was substantially lower in patients with superinfection (subhazard ratio
60 0.37, 95%-CI 0.15-0.90, $p=0.028$). Patients with pulmonary superinfections more often had
61 bacteraemia, virus reactivations, yeast colonization, and needed ICU treatment for a significantly
62 longer time.

63

64 Conclusions

65 The detection of superinfections was frequent and associated with reduced ventilator-free
66 survival. Despite empirical antibiotic therapy, superinfections lead to an extended ICU stay in
67 COVID 19 patients. Longitudinal microbiological sampling in COVID-19 patients could allow
68 targeted antimicrobial therapy, and therefore minimize the use of broad-spectrum and reserve
69 antibiotics.

70

71 Introduction

72 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolved as the most
73 relevant pandemic of modern history, challenging health care systems all over the world. The
74 clinical characteristics of coronavirus disease (COVID-19) patients have been thoroughly
75 described in recent studies (1-5). The triggers for acute respiratory distress syndrome (ARDS) in
76 COVID-19 are initially virus-initiated, subsequently leading to inflammation-mediated lung
77 damage and endothelitis (5). Although primarily a viral disease, antibiotics are empirically used
78 in over 70% of cases in addition to experimental antiviral and immunomodulatory treatments (1,
79 4-7).

80 Secondary bacterial and/or fungal infections are a well-described phenomenon in viral illnesses
81 such as influenza and are associated with increased morbidity and mortality in viral ARDS as
82 illustrated during previous pandemics (8). Secondary bacterial infections are typically referred to
83 as superinfections whereas co-infection is mainly used to describe simultaneous virus infection.
84 Both, co- and superinfection have been described in COVID-19 patients (6, 9). Data regarding
85 bacterial superinfections in COVID-19 pneumonia are limited and still emerging (10, 11). A
86 recent systematic review has concluded that the rate of bacterial/fungal superinfections is low
87 arguing against the frequent use of broad-spectrum antimicrobials in patients with COVID-19
88 (10, 12). Still, there is a lack of knowledge about the frequency and significance of bacterial,
89 fungal and viral concomitant infections in critically ill COVID-19 patients.(12) Additionally, in
90 most studies performed so far, no thorough and systematic sampling for concomitant infections
91 was performed. The high mortality in severely ill COVID-19 patients is thought to be at least in
92 part due to secondary infections in addition to viral replication in the lower respiratory tract
93 leading to severe lung injury and ARDS (6, 13, 14).

94 Superinfection seems to represent a major risk factor for mortality in COVID-19 patients (7, 15-
95 17). However, the risk of superinfection in mechanically ventilated patients with severe COVID-
96 19 remains poorly described.

97

98 Currently, the diagnostic and treatment approach for superinfections remains unclear. Classical
99 criteria for the detection of superinfections are often of limited use in COVID-19 patients.
100 Clinical symptoms are an expression of the underlying disease of COVID-19 and cannot be used
101 to reliably distinguish between patients presenting with or without relevant superinfections. For
102 this reason, several authors have argued in favour of an empirical antibiotic treatment with a
103 focus on streptococci and staphylococci in severe courses (14). Other opinion leaders

104 recommend longitudinal sampling of severely ill patients for early detection and treatment during
105 the entire course of the disease (6, 18).

106
107 Rapid diagnosis of co- and superinfection may not only help to improve survival but would also
108 allow targeted antimicrobial therapy, improving antimicrobial stewardship throughout the course
109 of the pandemic (18, 19).

110
111 The aim of our study was to assess the burden of superinfections and the association with clinical
112 outcomes in critically ill patients with COVID ARDS (CARDS) in a tertiary care ICU with
113 highly regulated antibiotic prescription (20).

Methods

Study design and population

This study was performed within the MicrobiotaCOVID cohort study. The MicrobiotaCOVID study is a single-centre, prospective observational study conducted at the Institute of Intensive Care Medicine of the University Hospital Zurich (Zurich, Switzerland) registered at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04410263).

Patients with confirmed SARS-CoV-2 infection and CARDS requiring ICU support and mainly invasive mechanical ventilation hospitalized between April 2020 and June 2020 during the first COVID-19 wave in Switzerland were eligible.

Inclusion criteria were age >18 years, SARS-CoV-2 infection as determined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) positivity of nasopharyngeal and/or pharyngeal swabs, TBS or BAL and hospitalization in the ICU for moderate or severe ARDS according to the Berlin criteria (21).

Exclusion criteria were patients or relatives denying informed consent and patients still being treated in the ICU when the study period ended.

Ethics and study registration

The study was approved by the local ethics committee of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 - 00646).

Study outcomes

The primary outcome was ventilator-free survival on day 28. Secondary outcomes were length of hospital stay, ICU stay and duration of ventilation. Further outcomes included the association of pulmonary superinfection and bacteraemia, other virus co-infections, colonisation with yeast, bacterial infections with multidrug resistance (MDR), and longitudinal laboratory inflammation parameters.

Sample collection, processing and testing

If the respiratory situation allowed bronchoscopy, BAL was collected upon ICU admission, and during the later course of the disease if medically indicated and upon discretion of the treating physicians. TBS was collected from each ventilated patient at least on day 0 (i.e. upon ICU admission), day 1, day 2, day 3, day 5 and henceforth every 5 days. If the clinical situation did not allow TBS collection, no sampling was performed.

Samples were processed at the Institute for Medical Microbiology and at the Institute for Medical Virology of the University of Zurich. Standard clinical microbiology techniques were used for culturing, isolation and identification of bacterial and fungal microorganisms as previously described (22). SARS-CoV-2 was detected by real-time RT-PCR as previously described (23).

At admission, multiplex PCR for respiratory syncytial virus (RSV) A/B, influenza A/B, adenovirus, coronavirus 229E, HKU1, NL63 and OC43, human bocavirus, human metapneumovirus (hMPV), rhino/enterovirus and parainfluenzavirus 1-4 was performed in nasopharyngeal swabs. Multiplex PCR for the detection of atypical respiratory bacteria was performed on pharyngeal swabs at ICU admission.

Moreover, we assessed serum detection and virus load of the following viruses: herpesviridae (herpes simplex type I and II (HSV 1 and 2), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human herpes virus 6 (HHV6). Additional virus diagnostics, blood and urine cultures were initiated by the treating physicians according to the clinical situation.

Data collection and covariates

Clinical and laboratory data were obtained from electronic health records and included demographics, comorbidities / risk factors, medication, ICU scores, laboratory values, organ failure, need for invasive ventilation, need for extracorporeal life support (ECLS), rescue therapies, length of ICU/hospital stay, and experimental therapy (steroids, hydroxychloroquine, lopinavir/ritonavir, remdesivir, tocilizumab and empiric antibiotic therapy).

Daily measurements of inflammatory parameters (CRP/PCT), the leukocyte count and the neutrophil/lymphocyte ratio were routinely performed over the first 16 days after ICU admission.

Definition of a clinically relevant microorganism in respiratory specimens (TBS and BAL) as a proxy for superinfection

The isolation of clinically relevant microorganisms from respiratory specimen cultures of critically ill COVID-19 patients (TBS and/or BAL) was used as a surrogate parameter for superinfection in concordance with clinical and radiological data. Patients were considered positive for clinically relevant microorganisms if the following pathogens were detected in TBS or BAL: *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella* spp., *Haemophilus influenzae*, *Escherichia coli*, *Enterobacter*, *Citrobacter* spp., *Pseudomonas aeruginosa*, and *Aspergillus* spp (24).

Consultants of the infectious disease department unrelated to the study group were involved daily in the diagnosis and management of patients including specific antimicrobial treatment. Organisms with low pathogenicity for lung infections such as *Enterococcus* spp., *Candida* spp., coagulase-negative Staphylococci and non-pneumococcal Streptococci were reported but not considered a relevant clinical pathogen of the airways in accordance with the literature (25). Detection of the herpesviridae herpes simplex 1 and 2 as well as cytomegalovirus, Epstein-Barr virus, human herpes virus 6 in blood were also reported but were considered to be reactivations. Viral co-infections/reactivations were only diagnosed if clinical signs of tracheitis or pathological signs of viral co-infection in cytology were observed.

Statistical analyses

Due to the unknown rate of concomitant infections in severely ill COVID-19 patients a power calculation was not feasible. Comparisons of population characteristics were performed using Mann-Whitney-U tests and the chi-squared/Fisher exact test for categorical variables, as appropriate. For longitudinal analysis of laboratory parameters, differences between time points and superinfection status were tested using linear mixed effects models. To estimate the effect of superinfections on 28-day ventilator-free survival, we used a competing risk regression model according to Fine & Gray censored at 28 days, with the event of extubation as outcome event and death as the competing risk. An alpha level of 0.05 was considered statistically significant. Statistical analysis was performed using STATA version 15 (StataCorp, College Station, TX), R version 3.6.3 (r-project.org/), SPSS Version 23 (SPSS Science, Chicago, IL, USA) and Graphpad Prism 7 (San Diego, CA, USA).

Results

Cohort characteristics

A total of 48 critically ill COVID-19 patients with ARDS were screened in ICU at the University Hospital Zurich between April and June 2020. Three patients had to be excluded from the analysis because patients or relatives denied informed consent (Figure 1). 45 patients with a median age of 60 (54-69) years were included in this study. Most of them were male (35/45, 77.8%). Of the 45 patients, 19 (42.2%) were diagnosed with a superinfection. The median of ventilation duration was 15 days and length of ICU stay was 14 days overall. The median length of hospital stay was 24 days. Baseline characteristics are summarised in Table 1. In general, both groups of patients with and without superinfections were similar with regards to demographics and clinical characteristics. In particular, there were no differences in the severity of the disease and organ dysfunction as assessed by SAPS II and SOFA scores. Intensive care rescue therapies such as prone position (42% vs 90%) and tracheotomy (23% vs 74%) were required more frequently and/or for longer periods in the superinfection group (Table 1).

Microbiological sampling and superinfections

Overall, 433 TBS, 35 BAL samples and 455 blood culture pairs were analysed for the presence of relevant microorganisms (Figure 1).

Clinically relevant microorganisms were detected in TBS in almost half the cases. In nineteen patients (42.2%) at least one clinically relevant bacterium or fungus was detected in TBS during the study period, whereas in 26 patients (57.8%) no relevant microorganisms were detected in TBS.

A total of 319 TBS were collected in the superinfection group and 124 relevant microorganisms were detected in these samples. Furthermore, relevant pathogens were detected six times in 23 BAL samples (26.1%). Only in two cases relevant results did not match between BAL and TBS. Despite high frequency of positive TBS, blood cultures showed only seven different bacterial species in twelve positive blood culture pairs (Figure 1).

In the group without superinfections, 83/114 TBS samples showed growth but without recovery of clinically relevant lung pathogens. *Candida albicans* was the most frequently isolated non-relevant organism. In BAL there was also no evidence of relevant microorganisms in the 12

samples. However, clinically relevant bacteraemia was detected twice in a total of 152 blood culture pairs (Figure 1).

The detection time points of clinically relevant and non-relevant microorganisms are depicted in Figure 2. On average, clinically relevant pathogens were detected on day ten after ICU admission and reflect the hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) spectrum (Figure 2A). Non-relevant pathogens were detected on average on day three post ICU admission (Figure 2B). The most frequently isolated bacteria per patient were detected: *Enterococcus* spp. (15/45), *Enterobacter/Citrobacter* (8/45) and *Klebsiella* spp. (7/45). Additionally, *Streptococcus pneumoniae* (2/45), *Escherichia coli* (2/45), *Enterobacter* spp. (5/45), *Citrobacter* spp. (3/45), *Pseudomonas aeruginosa* (5/45), *Burkholderia cepacia* (2/45) and Staphylococci (all coagulase-negative) (13/45)

Empirical antimicrobial therapy was given to 40/45 (88.9%) patients, antifungal therapy to 10/45 (22.2%) patients and antiviral therapy to treat concomitant viral infections to 9/45 (20 %) patients. Figures 2C and D summarize the antibiotic treatment.

In ten patients (22.2%) multi drug resistant (MDR) bacteria were detected (*Pseudomonas aeruginosa*, *Enterobacter cloacae* and *Burkholderia cepacia*).

Serum reactivation of HSV 1 and 2 was detected in 5 out of 45 patients. HHV 6 was detected twice, CMV reactivation occurred once and EBV reactivation twice. One patient had a co-infection with influenza A (Table 2).

Furthermore, colonisations with fungi were detected and the isolated organisms included *Candida* spp. (29/45 patients), non-*Candida* yeast (21/45 patients) and *Aspergillus* spp. (5/45 patients). A detailed overview of relevant pathogens detected in TBS and blood cultures are shown in Table 2.

Ventilator-free survival at 28 days

COVID-19 patients with pulmonary superinfections had a substantially lower 28-day ventilator-free survival than those without superinfections (Figure 3), with a subhazard ratio of 0.37 (95% Confidence Interval 0.15 – 0.90, $p = 0.028$).

Secondary outcomes

Patients with superinfections detected in respiratory specimens were ventilated for significantly longer time periods (8 vs 37 days, $p<0.001$) and had a significantly longer duration of stay in the ICU (9 vs 39 days, $p<0.001$) and overall hospitalization time (17 vs 44 days, $p<0.001$) as compared to patients without superinfections (Table 2).

Further outcomes

Patients with pulmonary superinfections had significantly more bacteraemia ($p=0.004$), virus co-infections other than SARS-CoV-2 ($p=0.001$), colonisation with yeast ($p=0.004$) and infections with MDR pathogens ($p<0.001$) (Table 2).

Longitudinal laboratory inflammation parameters (leukocytes, CRP, PCT and Neutrophil/Lymphocyte ratio) for days 1-16 are shown in Supplemental Figure 1A and Supplemental Table 1. Only for CRP, the mixed model evaluation showed a significant difference with increased CRP in the superinfection group ($p<0.001$). (Supplemental Figure 1 B, C and D).

Discussion

In this prospective cohort study of critically ill, ventilated COVID-19 patients the presence of respiratory bacteria as a proxy of superinfection was associated with extended ventilation times, increased duration of intensive care and hospitalization and increased need for intensive-care rescue therapies. Bacterial superinfections were detected in 42.2% of patients in our cohort, which is slightly higher than reported in previous studies (1, 2, 5, 6, 13, 14, 26). This discrepancy with other studies might be mainly due to the nature of our cohort consisting of severely ill patients with CARDS. In addition, differing from other studies, sampling was prospectively and repetitively scheduled and not only performed at admission as in other studies, which may account for under-reporting of superinfections. Regional differences can also play an important role especially in bacterial superinfections and spectrum of resistance. This can explain the increased rate of superinfections compared to the existing meta-analyses (10, 27, 28).

Although some studies have concluded that bacterial superinfections do not play a major role in disease severity and treatment choices, the results of the present study challenges the generalizability to severely ill CARDS patients (6, 10). In our cohort, isolation of relevant respiratory bacteria was associated with more severe COVID-19 disease courses with significantly longer duration of invasive mechanical ventilation and prolonged ICU and hospital stays. Compared to other studies investigating the role of superinfection in COVID-19, duration of ICU stay and length of ventilation was high, reflecting the disease severity of patients included in this study (7, 10). Additionally, data on the duration of ventilation and ICU stay are often missing in other studies making comparisons difficult (4, 10, 13, 29, 30). Furthermore, due to the comparatively high SOFA-Score upon admission but moderate mortality, as in our cohort, long-term ICU-treatment complications such as nosocomial infections become more frequent.

Relevant respiratory bacteria were isolated on average on day ten after ICU admission in our cohort suggesting mainly nosocomial infections. In contrast to bacterial superinfections observed in influenza pneumonia, COVID-19 superinfections with Gram-positive bacteria, such as *Pneumococci* or *Staphylococci*, were rare in this study (31). Similar observations were also made for MERS-CoV and SARS-CoV-1 associated superinfections (32-34). In this study, mainly Gram-negative pathogens such as *Pseudomonas* and *Enterobacteriaceae* including MDR bacteria were isolated, which is in line with previous reported studies (10).

Based on the finding that pulmonary bacterial superinfections seem to be mostly nosocomial, empirical broad-spectrum antimicrobial therapy could be stopped and only treated, if pathogenic

bacteria are detected (12, 30). Future prospective, randomized trials to investigate the efficacy of targeted antimicrobial therapy should be conducted to define best practice regarding prevention and treatment of bacterial superinfections in COVID-19. The isolation of mainly Gram-negative rods including MDR led to the use of reserve antibiotics after initial empirical therapy of nosocomial pneumonia (Figure 2). It is important to consider the short and long-term consequences that the use of antimicrobials, especially regarding broad spectrum and reserve antibiotics, may have on drug-resistance. A worrisome potential consequence of the COVID-19 pandemic might be the long-term spread of antimicrobial resistance (AMR) due to increased exposure of patients to antimicrobial agents that may have been used inappropriately (35). In this framework, employment of standardized longitudinal screening with early detection and susceptibility testing before establishment of targeted antimicrobial therapy, could minimize the use of broad-spectrum and reserve antibiotics, thus reducing AMR.

The high rate of yeast detection might be associated with the widespread use of broad-spectrum empirical antimicrobial therapy (36). Invasive aspergillosis was not detected (37, 38). So far, only few studies have investigated fungal superinfections in COVID-19 patients (13, 17, 39). The significance of viral reactivation remains unclear (10). In our study, reactivations of HSV 1, HSV 2 and HHV 6 in the serum occurred in patients with bacterial superinfections. These findings support the hypothesis that superinfections associated with increased COVID-19 disease severity might enhance susceptibility to viral reactivations. Further studies with higher participant numbers should clarify the significance of this finding.

In line with previous studies, conventional clinical laboratory tests such as leukocytes, PCT and neutrophil/lymphocyte ratio progressions were not associated with pulmonary superinfections and therefore do not seem very useful for the detection of bacterial superinfections in COVID-19 patients on mechanical ventilation. This complicates the diagnosis of bacterial superinfections and emphasizes the importance of longitudinal microbiological diagnostics.

Advantages of this study are the prospective longitudinal monitoring of respiratory materials with concomitant recording of demographic data, microbiological evaluations and antimicrobial therapy in a tertiary care centre in a high-resource setting that did not experience health care shortage during the first pandemic wave. Furthermore, this study used strict definitions for relevant respiratory pathogens and the diagnosis of superinfections was performed prospectively on defined days longitudinally with detection not only of bacterial but also fungal and viral super- and co-infections.

Limitations of the study are the single centre design, small number of patients and the high number of patients with empirical broad-spectrum antibiotic therapy (>90% of cases) at admission. Another limitation is the lack of a uniform internationally valid definition of a bacterial infection of the lower respiratory tract.

In summary, the detection of relevant bacterial pulmonary superinfection was associated with a more severe disease course in COVID-19 patients, especially a lower likelihood of ventilator-free survival at 28 days. Future trials should investigate the effect of tailored antimicrobial therapy on outcome, antibiotic resistance and drug use based on longitudinal assessment of respiratory tract cultures.

Transparency Declaration

Conflicts of interest

All authors declare no conflicts of interest in this paper.

Funding

Promedica Foundation 1449/M to SDB and unrestricted funds to RAS. The funders had no role in study design, performance, analysis and interpretation of findings.

Authors' contributions

PKB, ASZ, RAS, SDB designed the study and provided funding and infrastructure. PKB and SDB were responsible for the ethical approval. PKB, PWG, DAH, PMF and SDB performed the statistical analysis. PKB, ASZ, DAH, PDW, CTA, AGM, SMS, FA, MAM, JB, MPH, PMF, RAS and SDB collected, analysed and interpreted the data. PKB, DAH, SDB, ASZ and FA wrote the first draft of the manuscript.

All authors revised the manuscript and approved the final version.

373 References

- 374 1. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
375 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the
376 Lombardy Region, Italy. *Jama*. 2020.
- 377 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
378 2019 novel coronavirus in Wuhan, China. *Lancet* (London, England). 2020;395(10223):497-506.
- 379 3. Wendel Garcia PD, Fumeaux T, Guerri P, Heuberger DM, Montomoli J, Roche-Campo F, et al.
380 Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with
381 COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort.
382 *EClinicalMedicine*.
- 383 4. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory
384 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
385 *JAMA internal medicine*. 2020.
- 386 5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
387 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 388 6. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and
389 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial
390 prescribing. *Clin Infect Dis*. 2020.
- 391 7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
392 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* (London, England).
393 2020.
- 394 8. Martin-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al.
395 Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1)
396 virus. *Chest*. 2011;139(3):555-62.
- 397 9. Kreitmair L, Monard C, Dauwalder O, Simon M, Argaud L. Early bacterial co-infection in ARDS
398 related to COVID-19. *Intensive care medicine*. 2020:1-3.
- 399 10. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic
400 review and meta-analysis. *The Journal of infection*. 2020.
- 401 11. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection
402 among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
403 *Clinical Microbiology and Infection*. 2020.
- 404 12. Coppola S, Ciabattini A, Pozzi T, Castagna V, Bassi GL, Chiumello D. Hazardous mismatch
405 between pulmonary pathogens and antibiotic treatments in COVID-19 patients. *British journal of*
406 *anaesthesia*. 2020.
- 407 13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill
408 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
409 study. *Lancet Respir Med*. 2020;8(5):475-81.
- 410 14. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019
411 novel coronavirus disease in fever clinics. *Lancet Respir Med*. 2020;8(3):e11-e2.
- 412 15. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19:
413 A retrospective data analysis of 918 cases from a single center in Wuhan, China. *Infection control and*
414 *hospital epidemiology*. 2020;41(8):982-3.
- 415 16. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19
416 based on an analysis of data of 150 patients from Wuhan, China. *Intensive care medicine*. 2020.
- 417 17. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics
418 of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (London,
419 England). 2020;395(10223):507-13.
- 420 18. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in
421 COVID-19. *The Lancet Microbe*.
- 422 19. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and
423 Other Respiratory Pathogens. *Jama*. 2020;323(20):2085-6.
- 424 20. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia:
425 different respiratory treatments for different phenotypes? *Intensive care medicine*. 2020;46(6):1099-102.
- 426 21. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute
427 respiratory distress syndrome: the Berlin Definition. *Jama*. 2012;307(23):2526-33.
- 428 22. Frey PM, Marti GR, Droz S, de Roche von Arx M, Suter-Riniker F, Aujesky D, et al. Bacterial
429 colonization of handheld devices in a tertiary care setting: a hygiene intervention study. *Antimicrobial*
430 *resistance and infection control*. 2019;8:97.

23. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(3).
24. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;63(4):e1-e60.
25. Chastre J, Fagon JY. Ventilator-associated pneumonia. *American journal of respiratory and critical care medicine*. 2002;165(7):867-903.
26. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we expect? *Clin Infect Dis*. 2020.
27. Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, et al. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. *Anaesthesia, critical care & pain medicine*. 2020.
28. Tagarro A, Epalza C, Santos M, Sanz-Santaeufemia FJ, Otheo E, Moraleda C, et al. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. *JAMA pediatrics*. 2020.
29. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. *Jama*. 2020.
30. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. *Virus research*. 2020;285:198005.
31. Martin-Loeches I, van Someren Greve F, Schultz MJ. Bacterial pneumonia as an influenza complication. *Current opinion in infectious diseases*. 2017;30(2):201-7.
32. Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. Middle East Respiratory Syndrome. *N Engl J Med*. 2017;376(6):584-94.
33. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet Infectious diseases*. 2013;13(9):752-61.
34. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2005;18(1):1-10.
35. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. *The Journal of antimicrobial chemotherapy*. 2020.
36. de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, de Sousa Cartágenes MDS, Filho A, do Nascimento FRF, et al. Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. *Front Microbiol*. 2018;9:1351.
37. Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. *Mycoses*. 2020;63(6):528-34.
38. Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. *Critical care (London, England)*. 2020;24(1):299.
39. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis*. 2020.

475

Table 1. Demographic and clinical characteristics as well as risk factors of COVID-19 patients stratified according to presence or absence of relevant pathogens in tracheobronchial secretions (TBS) reflecting superinfection. The data are presented as median (IQR) or number and (percentage %). The two groups were compared using Chi-Square Test/Fisher Exact method for nominal distributed data or the Mann Whitney test for scale level distributed data. The significance level is $p < 0.05$.

	Overall (n=45)	No Superinfection (n=26)	Superinfection (n=19)	P-value
Baseline Characteristics				
Age median (IQR) in years	60 (54-69)	61.5 (54-71)	59 (54-69)	0.654
Male [n/%]	35 (77.8%)	19 (73.1%)	16 (84.2%)	0.375
Weight [kg]	83 (75-99)	80 (72.5-90)	92 (78-100)	0.049
Height [cm]	175 (165-182)	172 (160-180)	176 (169-185)	0.112
Body mass index [kg/m ²]	27.8 (25.7-31.6)	27.5 (25.6-30.6)	27.8 (26.8-35)	0.346
Comorbid conditions				
Myocardial Infarction / Ischemic Heart Disease	6 (13.3%)	5 (19.2%)	1 (5.3%)	0.222
Art Hypertension	26 (57.8%)	16 (61.5%)	10 (52.6%)	0.550
Chronic kidney disease	12 (26.7%)	10 (38.5%)	2 (10.5%)	0.047
Dialysis	1 (2.2%)	1 (3.8%)	0 (0%)	0.999
Oral hypoglycaemic agents controlled diabetes	5 (11.1%)	3 (11.5%)	2 (10.5%)	0.999
Insulin-dependent diabetes	14 (31.1%)	7 (26.9%)	7 (36.8%)	0.528
Asthma	1 (2.2%)	1 (3.8%)	0 (0%)	0.999
COPD	5 (11.1%)	4 (15.4%)	1 (5.3%)	0.378
Cardiovascular disease	7 (15.6%)	6 (23.1%)	1 (5.3%)	0.211
Renal or liver transplantation	5 (11.1%)	4 (15.4%)	1 (5.3%)	0.378
Immunosuppression	7 (15.6%)	5 (19.2%)	2 (10.5%)	0.222
Tumour disease	4 (8.9%)	2 (7.7%)	2 (10.5%)	0.999
Smoking	14 (31.1%)	7 (26.9%)	7 (36.8%)	0.625
Alcohol abuse	1 (2.2%)	0 (0%)	1 (5.3%)	0.999
Drug abuse	0 (0%)	0 (0%)	0 (0%)	1.000

Medical therapy before admission				
Statins	10 (22.7%)	6 (24%)	4 (21.1%)	0.999
ACE-Inhibitor	7 (15.9%)	4 (16%)	3 (15.8%)	0.999

Scores/Index				
Sepsis-related organ failure assessment score (SOFA)	8 (5-10)	8 (3-10)	9 (7-10)	0.480
Simplified Acute Physiology Score (SAPS) II	36 (25-50)	32.5 (24-50)	42 (28-51)	0.275
PaO2/FiO2 ratio low at admission	122 (94-177)	129 (97-200)	108 (85-163.5)	0.228

Organ failure during ICU stay				
Acute kidney disease	27 (60%)	15 (57.7%)	12 (63.2%)	0.712
Dialysis	18 (40%)	9 (34.6%)	9 (47.4%)	0.388
Ventilation Therapy	40 (88.9%)	21 (80.8%)	19 (100%)	0.043
Extracorporeal Life Support (ECLS)	8 (17.8%)	3 (11.5%)	5 (26.3%)	0.253

Rescue therapies				
Prone Position	28 (62.2%)	11 (42.3%)	17 (89.5%)	0.001
iNO	11 (24.4%)	5 (19.2%)	6 (31.6%)	0.341
Tracheotomy	20 (44.4%)	6 (23.1%)	14 (73.7%)	0.001

Timing [days]				
Time to ICU admission	2 (1-6)	2 (1-6)	3 (1-6)	0.636
Duration prone position	6 (1-10)	1.5 (1-7)	6 (4-10)	0.022
Duration iNO therapy	3 (1-6)	1 (1-3)	4.5 (1-22)	0.349
Duration Intubation to tracheotomy	20 (10-33)	10.5 (9-21)	27 (15-33)	0.114

Laboratory values at admission				
WBC count (G/L)	7.7 (5.7-10.7)	7.5 (5.7-10)	8 (5.3-13.4)	0.515
Haemoglobin (gr/l)	118.5 (101.5-133)	117 (107-132)	126 (98-134)	0.896
Haematocrit (%)	0.4 (0.3-0.4)	0.4 (0.3-0.4)	0.4 (0.3-0.4)	0.619
Platelet count (G/L)	199 (169.5-272)	200 (177-271)	190 (154-297)	0.776
ALT(U/L)	42.5 (25.5-65.5)	31 (24-60)	56 (33-72)	0.008
LDH (U/L)	676 (527-842.5)	619 (471-742)	772 (626-876)	0.144
Alkaline Phosphatase (U/L)	74.5 (53.5-103.5)	77.5 (56-108)	61 (53-98)	0.308

Urea (mmol/l)	6 (4.3-10.3)	6.2 (4.1-7.9)	6 (4.4-12.2)	0.651
Creatinine (umol/l)	92.5 (67-138.5)	95 (70-128)	91 (57-149)	0.387
Serum Sodium (mmol/L)	138 (134-141)	137 (135-140)	141 (134-146)	0.203
Serum potassium (mmol/L)	3.9 (3.7-4.5)	4.1 (3.7-4.4)	3.8 (3.5-4.7)	0.601
CRP (mg/L)	168.5 (83.5-276.5)	124 (62-238)	255 (102-301)	0.034
PCT (mcg/L)	0.3 (0.2-1.2)	0.2 (0.1-1.7)	0.4 (0.2-1.2)	0.060
IL6 (ng/L)	127 (71.2-454)	122 (84-697)	127 (62.7-263)	0.554

Special drug therapy				
Steroids	21 (46.7%)	8 (30.8%)	13 (68.4%)	0.012
Hydroxychloroquine	27 (61.4%)	13 (52%)	14 (73.7%)	0.143
Lopinavir/ritonavir	7 (15.9%)	4 (16%)	3 (15.8%)	0.999
Remdesivir	8 (18.2%)	4 (16%)	4 (21.1%)	0.704
Tocilizumab	2 (4.7%)	2 (8.3%)	0 (0%)	0.501
empiric antimicrobial therapy	40 (88.39%)	22 (88%)	18 (94.7%)	0.441

Sample size overall				
TBS	433	114	319	
BAL	35	12	23	
Blood culture	455	152	303	

Table 2 Clinical outcomes and microorganisms detected

The data are presented as median (95 CI of Median) or number and (percentage %). 95%CI of the difference or Relative Risk (95 CI) were calculated too. The two groups were compared using Chi-Square Test/Fisher Exact method for nominal distributed data or the Mann Whitney test for scale level distributed data. The significance level is $p < 0.05$.

	No Superinfection (n=26)	Superinfection (n=19)	95%CI of the difference or Relative Risk (95 CI)	p-value
Timing				
Duration ventilation	8 (5.9 - 15.1)	37 (22.2 - 43.7)	10 to 34	<0.001
Duration ICU	9 (7.0 - 14.9)	39 (28.5 - 57.0)	15 to 38	<0.001
Duration hospitalisation	17 (14.4 - 26.4)	44 (34.2 - 63.3)	10 to 41	<0.001
Superinfection data				
Patients died	6 (23.1%)	4 (21.1%)	0.95 (0.58 to 1.92)	0.999
Patients with bacterial respiratory superinfection	0 (0%)	19 (100%)		
Patients with superinfection in BAL	0 (0%)	6 (31.6%)	infinity (1.674 to infinity)	0.003
Patients with bloodstream infection	2 (7.7%)	9 (47.4%)	10.8 (1.92 to 53.53)	0.004
Patients with virus infection	1 (3.85%)	9 (47.4%)	7.143 (1.72 to 40.27)	0.001
Patients with aspergillus detection	2 (7.7%)	3 (15.8%)	1.5 (0.72 to 5.20)	0.636
Patients with Yeast detection	12 (46.2%)	17 (89.5%)	2.17 (1.33 to 3.51)	0.004
Patients with multi drug resistant pathogens	0 (0%)	10 (52.6%)	infinity (6.076 to infinity)	<0.001
Causative microbiology				
Microbiology of TBS superinfections				
Overall pathogen detection in TBS	83	368		
Relevant pathogen detection in TBS	0 (0%)	124 (33.7%)		
<i>Citrobacter freundii, koseri</i>	0 (0%)	8 (2.2%)		
<i>Enterobacter cloacae</i>	0 (0%)	9 (2.5%)		
<i>Escherichia coli</i>	0 (0%)	2 (0.5%)		
<i>Klebsiella aerogenes</i>	0 (0%)	8 (2.2%)		
<i>Klebsiella pneumoniae</i>	0 (0%)	18 (4.8%)		
<i>Legionella pneumophila</i>	0 (0%)	2 (0.5%)		
<i>Pseudomonas aeruginosa</i>	0 (0%)	49 (13.3%)		

<i>Streptococcus pneumoniae</i>	0 (0%)	2 (0.5%)
<i>Burkholderia cepacia</i>	0 (0%)	24 (6.5%)
<i>Morganella morganii</i>	0 (0%)	2 (0.5%)
Microbiology of bloodstream superinfections		
Overall relevant positive detection	2/152 (1.3%)	12/303 (4.0%)
<i>Citrobacter</i>	0 (0%)	2 (16.7%)
<i>Enterococci faecalis and faecium</i>	1 (50%)	6 (50%)
<i>Klebsiella aerogenes</i>	0 (0%)	1 (8.3%)
<i>Klebsiella pneumonia</i>	0 (0%)	1 (8.3%)
<i>Moraxella</i> spp	1 (50%)	0 (0%)
<i>Candida glabrata</i>	0 (0%)	1 (8.3%)
<i>Pseudomonas aeruginosa</i>	0 (0%)	1 (8.3%)
PCR diagnostic		
Atypical pneumonia pathogens (n=35)	0 (0%)	1 (%) (Legionella)
Causative virology superinfection		
Overall	2	9
Influenza A	0 (0%)	1 (11.1%)
Influenza B	0 (0%)	0 (0%)
Respiratory viruses block analysis (n=34)	0 (0%)	0 (0%)
HSV 1 (PCR in blood)	0 (0%)	5 (55.5%)
HSV 2 (PCR in blood)	0 (0%)	0 (0%)
HHV6 (PCR in blood)	0 (0%)	2 (22.2%)
CMV (PCR in blood)	1 (50%)	0 (0%)
EBV (PCR in blood)	1 (50%)	1 (11.1%)

Figure 1. Study Flow Diagram

Start of antibiotics
 Stop of antibiotics

excludes outside values

Proportion of ventilator-free survivors within 28 days

Number at risk					
Superinfection	19	16	16	12	11
No superinfection	21	13	5	3	1